Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin

By Bybee Kevin A.   Lee John H.   O'Keefe James H.  

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1217-1229

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin

By Jacobson Terry A.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 773-781

Informa Healthcare

Access to resources Recommend Favorite

Which Endpoints to Use in Clinical Trials in Venous Thromboembolism?

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 108-108

Karger

Access to resources Recommend Favorite

Differences between statins on clinical endpoints: a population-based cohort study

By Dieleman Jeanne P.   van Wyk Jacobus T.   van Wijk Marc A. M.   van Herpen Gé   Straus Sabine M. J. M.   Dunselman Hans   Sturkenboom Miriam C. J. M.  

Current Medical Research and Opinion, Vol. 21, Iss. 9, 2005-09 ,pp. : 1461-1468

Informa Healthcare

Access to resources Recommend Favorite

Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins

By Bergheanu Sandrin C.   Reijmers Theo   Zwinderman Aeilko H.   Bobeldijk Ivana   Ramaker Raymond   Liem An-Ho   van der Greef Jan   Hankemeier Thomas   Jukema J. Wouter  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2477-2487

Informa Healthcare

Access to resources Recommend Favorite